ASMB.OQ
Latest Trade
14.11USDChange
-0.40(-2.76%)Volume
208,059Today's Range
-
14.7952 Week Range
-
38.21As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 14.51 |
|---|---|
Open | 14.65 |
Volume | 208,059 |
3M AVG Volume | 6.04 |
Today's High | 14.79 |
Today's Low | 13.95 |
52 Week High | 38.21 |
52 Week Low | 10.62 |
Shares Out (MIL) | 25.71 |
Market Cap (MIL) | 381.05 |
Forward P/E | -3.91 |
Dividend (Yield %) | -- |
Assembly Biosciences Announces Appointment Of John Mchutchison As President And Chief Executive Officer
Assembly Biosciences Q2 Loss Per Share $0.72
Assembly Biosciences Q1 Loss Per Share $1.05
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Industry
Biotechnology & Drugs
Executive Leadership
William R. Ringo
Non-Executive Independent Chairman of the Board
John G. McHutchison
President, Chief Executive Officer, Director
Richard J. Colonno
Executive Vice President, Chief Scientific Officer
Jacqueline Sybil Papkoff
Senior Vice President, Chief Scientific Officer Microbiome
David R. Houck
Senior Vice President - Product Development and Portfolio Management
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 25.43 |
Price To Book (MRQ) | 2.18 |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | 0.00 |
LT Debt To Equity (MRQ) | 0.00 |
Return on Investment (TTM) | -53.16 |
Return on Equity (TTM) | -48.58 |
* ASSEMBLY BIOSCIENCES ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS
* ASSEMBLY BIOSCIENCES PRESENTS POSITIVE INTERIM DATA FROM PHASE 1A AND 1B STUDIES OF ABI-H0731 IN HBV PATIENTS IN A LATE-BREAKER SESSION AT THE EASL CONFERENCE
* ASSEMBLY BIOSCIENCES ANNOUNCES ADDITIONS TO MANAGEMENT TEAM AND BOARD OF DIRECTORS
* ASSEMBLY BIOSCIENCES FILES FOR MIXED SHELF OF UP TO $250 MILLION - SEC FILING Source text: (http://bit.ly/2CnCeGR) Further company coverage:
* ASSEMBLY BIOSCIENCES APPOINTS SUE MAHONY, PHD TO BOARD OF DIRECTORS
* Assembly biosciences announces pricing of $60 million offering of common stock
* Assembly Biosciences announces successful completion of ABI-H0731 phase 1A trial and upcoming conference presentations
* Will make upfront payment to assembly of $50 million for exclusive, worldwide rights to develop and commercialize UC, CD and IBS compounds
* Initiates phase 1 clinical program of abi-h0731 for treatment of chronic hepatitis b virus infection
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.